A parallel, open-label, single-dose study evaluating the efficacy, safety and pharmacokinetics of levomilnacipran extended-release (ER) in patients with mild, moderate or severe hepatic impairment and healthy volunteers.
Phase of Trial: Phase I/II
Latest Information Update: 05 Dec 2015
At a glance
- Drugs Levomilnacipran (Primary)
- Indications Hepatic infections; Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- 05 Dec 2015 New trial record